文献速递免疫规划传染病防控与疫情报告

针对人腺病毒3型、7型和55型的重组三价疫苗候选

A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55.
PubMed 文献 · Vaccine · 2018-03-13

研究构建了表达HAdV-55六邻体蛋白的重组三价疫苗候选rAdMHE3-h55,小鼠中和试验表明其可诱导针对HAdV-3、HAdV-7和HAdV-55的中和抗体,免疫后完全保护小鼠分别抵抗这三种型别攻击,肺部病毒载量更低、病理改变更轻。

要点

  • rAdMHE3-h55是在先前二价候选疫苗rAdMHE3的E3区表达HAdV-55六邻体蛋白构建而成。
  • 体外中和试验表明rAdMHE3-h55可在小鼠中诱导针对HAdV-3、HAdV-7和HAdV-55的中和抗体。
  • 免疫该三价疫苗候选后,小鼠分别抵抗HAdV-3、HAdV-7或HAdV-55攻击并获得完全保护。

核心结论

  • 重组三价疫苗rAdMHE3-h55可在小鼠中提供针对HAdV-3、HAdV-7或HAdV-55攻击的保护。
  • 未来对该疫苗候选的优化工作可能带来预防常见人腺病毒所致呼吸道疾病的更有效方法。

研究设计与样本

  • 研究构建了重组三价人腺病毒疫苗rAdMHE3-h55,在先前制备的针对HAdV-3和HAdV-7的二价疫苗候选rAdMHE3的E3区表达HAdV-55六邻体蛋白。
  • 采用体外中和试验检测小鼠中和抗体产生,并开展小鼠攻毒保护试验。

主要发现

  • 体外中和试验结果表明,rAdMHE3-h55可在小鼠中诱导针对HAdV-3、HAdV-7和HAdV-55的中和抗体。
  • 免疫重组三价疫苗候选后,小鼠分别抵抗HAdV-3、HAdV-7或HAdV-55攻击并获得完全保护。
  • 与未免疫小鼠相比,免疫小鼠肺部病毒载量更低、肺部病理改变更轻。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出未来需对该疫苗候选进行优化工作,可能带来更有效的预防方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human adenoviruses types 3 (HAdV-3), 7 (HAdV-7) and 55 (HAdV-55) are major pathogens of acute respiratory infections (ARI) in children and adults. More than one type of HAdV can infect patients simultaneously, and the infections are sometimes fatal. However, there is currently no vaccine approved for general use in children and adults. Thus, development of a multivalent HAdV vaccine to combat HAdV infection becomes imperative. In this study, we constructed a new recombinant trivalent human adenovirus vaccine (rAdMHE3-h55), which expresses the hexon protein of HAdV-55 in the E3 region of rAdMHE3, a previously prepared bivalent vaccine candidate against HAdV-3 and HAdV-7. The results of in vitro neutralization assays indicate that rAdMHE3-h55 can induce the production of neutralizing antibodies against HAdV-3, HAdV-7, and HAdV-55 in mice. Furthermore, immunization with the recombinant trivalent vaccine candidate completely protected the mice challenged with HAdV-3, HAdV-7, orHAdV-55, respectively, showing lower lung viral loads and less lung Pathological changes was compared with those in unvaccinated mice. The current findings contribute to the development of a new adenovirus vaccine candidate and also advance this construction method for the generation of recombinant adenovirus vaccines. In conclusion, our recombinant trivalent vaccine rAdMHE3-h55 can provides protection against challenge with HAdV-3, HAdV-7, or HAdV-55 in mice. Future work of optimizing this vaccine candidate may lead to a more effective way of preventing respiratory diseases caused by common human adenoviruses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu T, Zhou Z, Tian X, et al. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine. 2018. PMID: 29548605. doi:10.1016/j.vaccine.2018.02.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。